Vanderbilt University

1. Novartis Pharmaceuticals Corporation $1,728,262 7 payments
2. Pfizer Inc. $1,145,472 82 payments
3. Genentech, Inc. $1,075,373 111 payments
4. Neurocrine Biosciences, Inc. $835,035 59 payments
5. Merck Sharp & Dohme Corporation $734,613 21 payments
6. Boston Scientific Corporation $489,893 81 payments
7. Medivation Inc. $462,257 22 payments
8. Takeda Pharmaceuticals U.S.A., Inc. $430,681 12 payments
9. Shire North American Group Inc $333,515 24 payments
10. Daiichi Sankyo Inc. $306,818 31 payments

1. A Phase Ib and Or II Multicenter Study of the Combination of Lee011 and Byl719 With Letrozole in Adult Patients With Advanced Er Plus Breast Cancer $1,687,947 4 payments
2. A Phase 2 Randomized Doubleblind Placebocontrolled Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen Or Progesterone Receptorpositive and Her2normal $777,265 35 payments
3. Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease $640,879 45 payments
4. A Phase Ibii Trial of Atezolizumab An Anti-Pd-L1 Monoclonal Antibody With Cobimetinib A Mek12 Inhibitor Or Idasanutlin An Mdm2 Antagonist in Metastatic Er Breast Cancer $419,682 2 payments
5. Hospitalized pneumococcal community acquired pneumonia in adults - US $358,566 11 payments
6. A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B $352,040 1 payment
7. A Phase Ib II Trial of Atezolizumab With Carboplatin in Patients With Ar Negative Metastatic TNBC $307,280 10 payments
8. Ds3201-A-U102 $306,818 31 payments
9. PevAz: A phase II trial of Pevonedistat and Azacitidine in MDS or MDS/MPN patients who fail primary therapy with DNA methyltransferase inhibitors $289,630 2 payments
10. An Open-Label Extension to Study Hgt-Hit-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Administration of Idursulfase-It in Pediatric Pateints With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and $281,256 14 payments

1. Other $143,928 14 payments
2. Professional salary support $137,128 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.